Industry

Managed Health Care — Understanding the Playing Field

Molina is a pure-play government-sponsored health insurer. It does not sell coverage to employers or the affluent; it is paid by U.S. taxpayers — state Medicaid agencies and the federal Medicare and Marketplace programs — to take medical risk on low-income, elderly, and disabled Americans. As of December 31, 2025 it served roughly 5.5 million members across 21 states, and was founded in 1980 as a clinic for low-income families in Southern California [1]. To read the rest of this report you need a working model of three things: how this business actually makes money, why 2025 was the worst margin year the sector has seen in a decade, and who Molina competes against. This tab builds that model — every material figure links to the filing page that proves it.

1. How the money works: a thin-margin, risk-bearing utility

The model is simple to state and brutal to run. A government pays the plan a fixed per-member-per-month (PMPM) premium; in exchange, the plan arranges and pays for all of that member's covered care and keeps whatever is left [2]. The plan is at risk: if members use more care than the premium assumed, the plan eats the difference. There is no markup on a product and no inventory — the "cost of goods" is human illness, estimated by actuaries months before the bills arrive.

Source: FY2025 Form 10-K, Financial Highlights [3]; revenue per company financials, as reported.

Because almost the entire premium is consumed by claims, the economics are a razor. The ladder below walks Molina's 2025 premium dollar down to net income: from $43.1B of premium, ~$39.5B left immediately as medical costs, leaving a $3.6B underwriting margin that administrative cost (an industry-low ~6.5% G and A ratio), taxes, interest, and fees then ground down to $472M of net income — roughly one penny of profit per premium dollar.

Source: derived from FY2025 Form 10-K Financial Highlights and segment data — premium revenue and MCR [4]; segment premium and margin [5].

The investing lesson sits in that last row. When margin is one penny, a 1-percentage-point miss on the MCR roughly halves earnings. That is precisely what happened in 2025: net income fell from $1,179M to $472M and EPS from $20.42 to $8.92 even as revenue rose, because the MCR climbed from 89.1% to 91.7% [6]. High operating leverage to medical cost is the defining feature of the whole sector.

2. The three demand pools

Government-sponsored coverage is not one market but three, each with a different payer, contract length, and risk profile. Molina runs all three (plus an immaterial "Other" segment) [7].

Source: FY2025 Form 10-K, Segment Membership and Segment Premium Revenue [8].

Medicaid (75% of premium) — the core. Established in 1965 under the Social Security Act, Medicaid covers low-income Americans and is jointly funded by Washington and the states but operated by each state, which gives states wide latitude over eligibility, benefits, and rates [9]. The federal government reimburses states a share of cost — the Federal Medical Assistance Percentage (FMAP), averaging about 60% across jurisdictions [10]. States hire managed-care plans like Molina through competitive Requests for Proposal (RFPs), awarding contracts that typically run three to five years; Medicaid made up 75% of Molina's premium in 2025, with California, New York, Texas, and Washington each contributing roughly 10% or more [11]. Rates must by law be "actuarially sound," but the state sets them — so the central tension of the business is whether the state's rate keeps pace with the plan's actual cost trend [12].

Medicare (14%) — the duals pivot. Medicare is a federal program for those 65+ and certain disabled people. The strategic prize is the roughly 12 million "dual-eligible" Americans who qualify for both Medicare and Medicaid — frailer, costlier, and the natural overlap for a Medicaid-heavy insurer [13]. Molina is deliberately reshaping this segment around duals: it is exiting its standalone Medicare Advantage (MAPD) product for 2027 — a product that was 25% of Medicare premium in 2025 — to focus on integrated dual plans (D-SNPs) [14].

Marketplace (10%) — the volatile one. The Affordable Care Act created the Marketplace exchanges in 2014, where individuals buy federally subsidized coverage through premium tax credits and pick from Bronze/Silver/Gold metal tiers [15]. It is the most unpredictable pool — one-year contracts, annual re-pricing, and acute sensitivity to whoever enrolls. Molina is deliberately shrinking Marketplace ~50% in 2026 (toward ~220k members) to protect margin as enhanced ACA subsidies lapse [16].

3. The cycle: rate-versus-trend is the whole game

This industry does not progress smoothly — it oscillates around the gap between the premium rate the government grants and the medical cost trend the plan actually incurs. Because state rates are set annually and lag changes in cost trends, a sudden acceleration in medical cost flows straight to the bottom line before rates can catch up [17]. That is exactly the pressure of 2023–2025.

Source: company segment results, as reported; FY2025 level confirmed in FY2025 Form 10-K [18].

The MCR sat near a benign ~88% through 2022–2023, then ratcheted up through 2024 and spiked to 94.6% in Q4 2025 before easing to 91.1% in Q1 2026 [19]. Management frames the drivers precisely: Medicaid medical cost trend ran 4.5% in 2023, 6.5% in 2024, and 7.5% in 2025 — leaving the cost baseline roughly 20% higher than three years earlier — while two forces piled on. First, an acuity shift: as states unwound pandemic-era continuous enrollment ("redeterminations"), healthier, low-utilizing members dropped off the rolls, leaving a sicker, costlier residual pool [20]. Second, state rates simply lagged the inflection [21].

Source: Q1 FY2026 earnings call — three-year trend and 2026 assumptions [22]; 2026 cost-trend and rate guidance [23].

For 2026, Molina assumes a ~5% medical cost trend against ~4% Medicaid rate updates — still a gap, but a narrowing one, and the acuity-shift pressure now appears largely spent [24]. The cyclical thesis from here is mean-reversion: as states "catch up" to the higher cost baseline with retro and off-cycle rate increases, the rate-trend balance corrects and margins should expand [25].

4. Competitive structure: a regulated oligopoly of giants

The industry is highly competitive at national, regional, and local levels, and plans compete for state contracts, members, provider networks, and brokers [27]. But the field is dominated by a handful of very large companies. Molina names its primary Medicaid competitors as Centene, CVS Health, Elevance Health, and UnitedHealth Group [28]; in Medicare its rivals are CVS, Humana, and UnitedHealth, and in low-income Marketplace its chief competitor is again Centene [29].

The scale gap is enormous, and it frames Molina's strategic position as the small, focused specialist in a field of diversified behemoths.

Sources: MOH per company financials [30]; UNH consolidated revenue [31]; Centene revenue [32]; CVS, Elevance, Humana scale approximated from filings (membership cited below).

Sources: Centene 27.6M members / $194.8B / largest Medicaid (12.5M) and Marketplace (5.5M) carrier [33][34][35]; UNH Community and State 7.4M and MA 8.4M [36]; CVS/Aetna 37M [37]; Elevance 45.2M [38]; Humana 15M / 83% federal [39]; Molina [40].

What protects these incumbents — and what doesn't. The barriers to entry are real but unusual. To win a state contract a plan needs a built-out provider network, care-management capability, regulatory licenses, state-level solvency capital, and a track record — incumbency and reputation matter heavily in RFP scoring [41]. But the moat is leaky: contracts are rebid every few years, incumbency does not guarantee renewal, and large national plans are pressing back into Medicaid [42]. Molina lost its Virginia contract on rebid in 2025, a reminder that a single RFP loss can erase a state's worth of revenue. The other structural feature: the customer is the government and the supplier set is concentrated — Molina even outsources its entire pharmacy benefit to CVS Caremark, a direct competitor in the insurance line [43].

5. Regulation is the operating system, not the weather

In most industries regulation is a constraint on the business. Here it is the business: the government sets the premium, defines the product, decides who is eligible, and can change all three. Molina's plans are "highly regulated by both state and federal government agencies," with rules that "change frequently" [44]. For an investor, that means the most important catalysts are not products or pricing but legislation and rule-making. The current docket is unusually heavy.

Sources: OBBBA provisions and 15-20% Expansion impact [45]; Marketplace Program Integrity Rule and subsidy expiry [46]; duals integration and Star Ratings [47].

The headline risk is the One Big Beautiful Bill Act (OBBBA), signed in July 2025. It requires states to add work requirements, more-frequent eligibility redeterminations, and cost-sharing to the Medicaid Expansion population over 2027–2029, and limits the provider taxes states use to fund their share [48]. Molina estimates this will cut enrollment 15% to 20% on its 1.2 million Expansion members by 2029 [49]. Layered on top, the expiration of enhanced ACA subsidies at the end of 2025 and a new Marketplace integrity rule both shrink the exchange pool and can leave it sicker [50]. The opportunity sitting alongside the threat is duals integration: CMS rules pushing dual-eligible members into a single company's aligned Medicare-Medicaid plan reward exactly the overlapping footprint Molina (and Centene) have built [51].

6. Where the industry sits — and the watchlist

Managed care is a mature, cyclical, defensively-positioned utility: structural demand is durable (an aging population and ~80M+ Americans on Medicaid), growth is steady mid-single-digit, but profitability swings hard on the rate-versus-trend cycle and on the political winds. The sector entered 2025 at a cyclical margin trough; the investment debate over the rest of this report is whether 2026–2027 is the recovery off that trough or a lower-for-longer reset driven by OBBBA.

Sources: rate catch-up, cost-trend, and consolidation commentary [52]; margin-expansion path [53]; OBBBA and ACA subsidy detail [54][55].